Elizabeth Buck

Founder at BLACK DIAMOND THERAPEUTICS, INC.

Net worth: 377 826 $ as of 2026-05-30

51 year

5 connections

Consumer Services

Producer Manufacturing

Health Technology

Profile

Elizabeth Buck is the founder of Black Diamond Therapeutics, Inc. since 2014, holding the title of Chief Scientific Officer.
Former job at OSI Pharmaceuticals, Inc. from 2005 to 2013 as Assistant Director-Advanced Preclinical.
Former job at MetaStat, Inc. from 2013 to 2014 as Chief Scientific Officer-Therapeutics.
Education includes an undergraduate degree from the University of New Hampshire and a doctorate from Icahn School of Medicine at Mount Sinai.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
BLACK DIAMOND THERAPEUTICS, INC. 0.3%	2026-01-20	170,192 ( 0.3% )	377 826 $	2026-05-30

Elizabeth Buck active positions

Companies	Position	Start
BLACK DIAMOND THERAPEUTICS, INC.	Founder	2013-12-31

All active positions of Elizabeth Buck

Former positions of Elizabeth Buck

Companies	Position	End
METASTAT, INC.	Chief Tech/Sci/R&D Officer	2014-11-30

See the detail of Elizabeth Buck's experience

Training of Elizabeth Buck

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Elizabeth Buck's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
University of New Hampshire University of New Hampshire Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
MetaStat, Inc. MetaStat, Inc. Electrical ProductsProducer Manufacturing Develops cancer diagnostics technologies	Producer Manufacturing
Black Diamond Therapeutics, Inc. Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer	Health Technology